NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(13 sites)

United States

Children's Hospital Los Angeles, Los Angeles, California

UCSF Benioff Children's Hospital, San Francisco, California

Children's Hospital Colorado, Aurora, Colorado

Comer Children's Hospital, University of Chicago, Chicago, Illinois

Boston Children's Hospital, Dana-Farber Cancer Institute., Boston, Massachusetts

C.S Mott Children's Hospital, Ann Arbor, Michigan

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Nationwide Children's Hospital, Columbus, Ohio

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

St. Jude Children's Research Hospital, Memphis, Tennessee

University of Texas Southwestern, Dallas, Texas

Cook Children's Medical Center, Fort Worth, Texas

Seattle Children's Hospital, Seattle, Washington